drugset
Drugs / 5-aminolevulinic acid nanoemulsion
last change Mar 2018 re-read 3 minutes ago

5-aminolevulinic acid nanoemulsion

also known as Ameluz · BF-200 ALA
Developed for
lentigo
Investigated by
Huslab, Finland · Joint Authority for Päijät-Häme Social and Health Care · Tampere University

Trials 1

today NCT02685592 · Ph 4
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02685592 Feb 2016 → Mar 2018 lentigo Joint Authority for Päijät-Häme Social and Health Care Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 5-aminolevulinic acid nanoemulsion ClinicalTrials.gov intervention name — accepted as the source's own label NCT02685592 ↗
Known as Ameluz “using 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) as a light sensitizing cream” NCT02685592 ↗
Known as BF-200 ALA “using 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) as a light sensitizing cream” NCT02685592 ↗